TD2 Precision Oncology

Executive Summary

TD2 Precision Oncology is a specialized contract research organization (CRO) focused exclusively on oncology, headquartered in Scottsdale, Arizona since 2003. The company offers integrated services spanning preclinical model systems, clinical trial management, regulatory support, and advanced flow cytometry analytics, enabling biopharma clients to advance novel cancer therapies from discovery to regulatory approval. With over two decades of domain expertise, TD2 positions itself as a niche partner capable of accelerating oncology drug development through tailored, high-quality research solutions. Its deep understanding of tumor biology and translational science allows it to support both early-stage startups and established pharmaceutical companies in navigating the complexities of cancer drug development. As a privately held, pre-clinical stage company without disclosed funding or valuation, TD2's growth is tied to its ability to secure repeat contracts and expand its service portfolio in a competitive CRO market. The oncology CRO sector benefits from rising R&D spending in cancer therapeutics, particularly in immuno-oncology and targeted therapies. TD2's differentiated focus on precision oncology and its established infrastructure in preclinical modeling and biomarker analysis could drive client acquisition and retention. However, the lack of public financial data and limited visibility into its pipeline suggest moderate near-term revenue predictability.

Upcoming Catalysts (preview)

• Q3 2026Major pharmaceutical partnership or multi-year contract announcement60% success
• Q4 2026Launch of a new service line in immuno-oncology biomarker analysis45% success
• Q2 2026Expansion of preclinical model portfolio with patient-derived xenografts (PDX) for rare cancers50% success